For years, getting started on medication for opioid use disorder meant an in-person visit was often required before a prescription could be written a real barrier for people in rural areas, without transportation, or simply without an available appointment during a moment when starting treatment mattered. That's changed substantially, and it's worth understanding exactly what the current rules actually allow.
In January 2025, the DEA and HHS finalized a rule permanently extending telemedicine flexibilities specifically for buprenorphine prescribing meaning a provider can prescribe buprenorphine for opioid use disorder via audio-video or audio-only telehealth, without requiring an initial in-person visit first. That final rule took effect December 31, 2025.
Separately, the DEA has repeatedly extended broader telemedicine flexibilities covering other controlled substances used in addiction treatment, including methadone and naltrexone most recently through a fourth temporary extension running through December 31, 2026, while the agency continues finalizing a permanent framework.
- No in-person visit required to start treatment. A qualified provider can conduct an initial assessment and begin prescribing buprenorphine entirely through telehealth.
- Audio-only visits count. This matters significantly for people without reliable video/internet access a phone call alone can be sufficient for an eligible visit.
- Up to six months of prescribing without an in-person visit under the finalized buprenorphine rule a substantial extension from the shorter window originally proposed.
- This applies across patient populations the data shows have particularly benefited: veterans, people in rural areas, people experiencing homelessness, people involved in the criminal legal system, and others facing real logistical barriers to in-person care.
The policy rationale is grounded in outcome data: expanded telehealth access to buprenorphine has been associated with more people starting and staying in treatment, without an associated increase in overdose deaths a combination regulators specifically cited in extending and finalizing these flexibilities rather than letting them lapse.
A few things are worth being clear-eyed about:
- This is still a temporary framework for non-buprenorphine controlled substances. The broader telemedicine flexibilities (covering methadone, naltrexone, and other Schedule II–V medications) are extended year-to-year while DEA and HHS finalize permanent rules worth confirming current status if reading this after 2026, since the framework has changed annually.
- State laws still apply. Federal flexibility doesn't override state-level telehealth or prescribing requirements, which vary and are worth confirming for your specific location.
- Methadone dispensing itself still generally requires in-person visits at a certified opioid treatment program for actual medication dispensing, even where telehealth is used for aspects of assessment or counseling this is a different regulatory framework than buprenorphine prescribing specifically.
- A qualified provider relationship still matters. Telehealth removes the in-person requirement; it doesn't remove the need for a licensed provider conducting a genuine clinical assessment.
- Scheduling an initial assessment with a telehealth provider or platform offering MAT services
- A clinical intake covering substance use history, current symptoms, and relevant medical history conducted by video or phone
- A prescription sent electronically to a local pharmacy if buprenorphine is determined appropriate
- Ongoing follow-up visits, typically also via telehealth, for monitoring and prescription renewal
- People in rural areas without a nearby addiction medicine provider
- People without reliable transportation
- People whose work schedule makes in-person appointments difficult
- People for whom the privacy of a telehealth visit reduces a real barrier to seeking care at all
Many telehealth platforms now specialize specifically in MAT, alongside a growing number of traditional addiction treatment providers offering telehealth options directly. SAMHSA's national treatment locator can help identify options, and it's reasonable to ask any provider directly whether they offer telehealth-based buprenorphine treatment and what their specific intake process looks like.
Frequently asked questions
No under the finalized 2025 rule, a provider can conduct an initial assessment and prescribe buprenorphine entirely via telehealth, including audio-only visits, without requiring an in-person visit first.
The buprenorphine-specific rule is now permanent as of the finalized January 2025 rule. Broader telehealth flexibilities for other controlled substances used in addiction treatment remain on a temporary, annually extended framework as of 2026, pending a permanent policy.
Methadone dispensing still generally requires in-person visits at a certified opioid treatment program, even though some aspects of care may be supported through telehealth this is a different regulatory framework than buprenorphine prescribing.
Outcome data cited by federal regulators has shown telehealth access improving treatment initiation and retention without an associated increase in overdose deaths, supporting the case for these flexibilities, though individual circumstances and the complexity of a person's situation can affect whether telehealth alone is sufficient.
Most insurance plans, including Medicaid, are required to cover substance use disorder treatment at parity with in-person medical care, which generally extends to covered telehealth visits confirming specific coverage with your plan directly is still worthwhile.
Audio-only telehealth visits are explicitly permitted for buprenorphine treatment under current rules, specifically to address this exact barrier a phone call alone can be sufficient for an eligible visit.
This article was reviewed by the RehabsNearMe Editorial Team for accuracy, clarity, and relevance. Information may be sourced from publicly available treatment resources, government agencies, and healthcare references where applicable.
Last reviewed: August 2026
Related articles
Resources
